CTLA4 and neoplasm: A study was conducted to identify factors associated with success or failure of checkpoint therapy, in which they performed transcriptomes analysis in immune cells from tumor samples of melanoma patients treated with checkpoint therapy (anti-PD-1, anti-CTLA4+PD-1, and anti-CTLA4).